Bajaj Finserv Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?

Bajaj Finserv Healthcare Fund Direct Growth Plan has a NAV of ₹12.084 as of 15 Sep 2026 and an AUM of ₹405 Cr. Its 1-year, 3-year and 5-year returns are 20.48%, 0%, and 0% respectively, and it sits in the High Risk bucket. Our view is that the fund has shown a strong one-year run, but its short history means the longer track record is still too limited to judge the full cycle.

The fund may suit investors who want healthcare exposure and can accept sharp swings. The portfolio is concentrated in a handful of large healthcare names, which can amplify both gains and drawdowns when the sector moves.

Quick facts

Particular	Details
NAV	₹12.084 as of 15 Sep 2026
AUM	₹405 Cr
Expense Ratio	0.72%
Launch Date	27 Dec 2024
Min SIP	₹500
Risk Category	High Risk
Benchmark	Nifty 50
Fund Category	Equity
Exit Load	1% on or before 3M, Nil after 3M
Fund Managers	Vinay Bafna, Bharat Hegde, Siddharth Chaudhary

The fund is managed by Vinay Bafna, Bharat Hegde, and Siddharth Chaudhary.

Source data date: as of 15 Sep 2026

Performance

Period	Fund return	Benchmark return
1M	0.22%	-4.81%
3M	12.68%	-3.63%
1Y	20.48%	-8.27%
3Y	Data not available	Data not available
5Y	Data not available	Data not available

The one-month picture is modest, but the fund still held a small gain while the benchmark slipped. The three-month stretch is much stronger, with a double-digit fund return versus a negative benchmark return. That tells us the fund has recently benefited from a clear sector-specific recovery even though the broader market benchmark stayed weak.

Over 1 year, the fund’s 20.48% return stands well above the benchmark’s -8.27%. That gap is large enough to show meaningful outperformance over the period, but it also reflects the fund’s sector focus rather than broad-market participation. For investors, that matters because healthcare-oriented performance can diverge sharply from a general index.

The daily path over the recent periods also suggests a choppy but improving trend rather than a smooth climb. There were small pullbacks along the way, yet the recovery later in the period was more persistent. Because the fund launched only in late 2024, there is not yet a full long-term cycle here, so the recent strength should be read as encouraging but still early in the scheme’s life.

Source data date: as of 15 Sep 2026

Should you BUY or HOLD Bajaj Finserv Healthcare?

A fund's past returns alone don't tell you whether you should buy it today or continue holding it.

The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.

Already holding Bajaj Finserv Healthcare? Thinking of investing now?

Get your portfolio analysed for FREE by SEBI-registered Investment Adviser (RIA) through Univest MF Premium

Peer comparison

Fund	1Y return	3Y return	5Y return
Bajaj Finserv Healthcare Fund Direct Growth Plan	20.48%	Data not available	Data not available
ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan	69.16%	37.12%	Data not available
HDFC Pharma and Healthcare Fund Direct Growth Plan	27.47%	Data not available	Data not available
SBI Automotive Opportunities Fund Direct Growth Plan	27.05%	Data not available	Data not available
Kotak Healthcare Fund Direct Growth Plan	26.51%	Data not available	Data not available
Motilal Oswal Active Momentum Fund Direct Growth Plan	25.46%	Data not available	Data not available

This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. On the 1-year view, this fund trails several of the listed comparables, especially the stronger sector- and theme-oriented peers that have posted higher gains. The short-term comparison therefore looks mixed: the fund is positive, but not as strong as the best available peer returns.

On the longer-horizon columns, most peers in the list do not yet have usable 3-year or 5-year figures, so the comparison is incomplete. The only peer with a 3-year figure is the metal-and-energy FoF, which has been far stronger on that measure. That said, the available peer set does not tell one single story: the fund’s 1-year showing is respectable, but it does not match the standout one-year numbers at the top of the list.

Source data date: as of 15 Sep 2026

Portfolio: where your money goes

Holding	Sector	Weight
Divi'S Laboratories Limited	Healthcare	10.55%
Sun Pharmaceutical Industries Limited	Healthcare	8.21%
Rubicon Research Limited	Domestic Equities	6.81%
Piramal Pharma Limited	Healthcare	6.72%
Aurobindo Pharma Limited	Healthcare	6.18%
Apollo Hospitals Enterprise Limited	Healthcare	6%
Torrent Pharmaceuticals Limited	Healthcare	5.03%
Neuland Laboratories Limited	Healthcare	4.11%
Emcure Pharmaceuticals Limited	Healthcare	3.84%
Max Healthcare Institute Limited	Healthcare	3.35%

The largest holding, Divi'S Laboratories Limited, is 10.55%, which is large enough to matter on its own, but not so large that one stock dominates the entire portfolio. The fall from the first holding to the tenth is gradual rather than abrupt, moving from double-digit weight into the low-single-digit range. That pattern suggests the fund uses a core of meaningful positions rather than relying on a single outsized bet.

The top 10 holdings together account for approximately 60.8% of the portfolio, and the fund has 34 disclosed holdings in total. That combination points to a portfolio that is fairly concentrated at the top while still retaining a longer tail of smaller positions. In practice, the larger healthcare names are likely to have greater influence on returns, while the smaller holdings may add diversification but with less impact on day-to-day performance.

Because most of the listed holdings are in healthcare, the portfolio remains tightly linked to sector trends. Rubicon Research Limited is the only top-10 holding labelled outside healthcare, which reinforces the fund’s sector focus and means performance may move differently from a broad market fund.

To see all holdings, visit the Bajaj Finserv Healthcare Fund Direct Growth Plan page

Source data date: as of 15 Sep 2026

Who should invest

This fund may suit investors who can tolerate High Risk and are comfortable with healthcare-sector swings. Its recent return pattern is encouraging, but the absence of a longer live track record means the fund is still building its history.

It is better viewed with a medium-to-long horizon, because sector-focused funds can move sharply over shorter periods and may not track the broad market closely. Investors who want steady, benchmark-like behaviour may find the divergence uncomfortable, while those seeking targeted healthcare exposure may see the trade-off as acceptable.

Tax and exit load

Holding period	Tax rate	Description
Units held less than 1 year	20%	Short-term capital gains tax
Units held more than 1 year	12.5%	Long-term capital gains tax

Exit load applies at 1% if units are sold within 3 months, and it is nil after 3 months.

Source data date: as of 15 Sep 2026

Frequently asked questions

What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth Plan?

The current NAV is ₹12.084 as of 15 Sep 2026.

What are the fund’s 1-year, 3-year and 5-year returns?

The fund’s 1-year return is 20.48%. Its 3-year and 5-year returns are not available because the scheme is too new for those periods.

How has the fund performed against the benchmark?

It has outperformed the Nifty 50 over the available time frames. The fund shows 0.22% over 1 month, 12.68% over 3 months and 20.48% over 1 year, while the benchmark is negative across those same periods.

How does it compare with the listed peer funds?

The fund’s 1-year return is lower than several of the listed peers, including HDFC Pharma and Healthcare Fund Direct Growth Plan at 27.47% and Kotak Healthcare Fund Direct Growth Plan at 26.51%. The peer set has limited usable 3-year and 5-year data, so longer-horizon comparison is incomplete.

Is there a minimum SIP amount?

The minimum SIP amount is ₹500.

What are the risk profile, portfolio style and exit load?

The fund is marked High Risk and its top holdings are led by healthcare names such as Divi'S Laboratories Limited, Sun Pharmaceutical Industries Limited and Piramal Pharma Limited. Exit load is 1% if units are sold within 3 months, and nil after 3 months.

Bottom line

Bajaj Finserv Healthcare Fund Direct Growth Plan has delivered a strong recent showing, but its short history means the longer-term picture is still incomplete. The available peer comparison is mixed: several comparable themes have stronger 1-year numbers, while the peer set offers little usable long-horizon evidence for most funds. The portfolio is heavily tilted toward healthcare stocks, so the fund may appeal to investors who want focused sector exposure and can live with High Risk behaviour rather than broad-market steadiness.

Published on 16 September 2026 at 9:07 AM IST

Explore mutual funds with Univest

Review mutual fund data, compare performance and explore fund insights on Univest.

Explore Univest

RIA disclosure

Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.